ZTS — Zoetis Inc. Stock Price, Chart & AI Report

Negative Jul 16, 2026 • 18:12 UTC GlobeNewswire Inc. • Rosen Law Firm

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period of January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its flagship products Librela, Simparica Trio, and dermatology treatments Apoquel and Cytopoint due to safety concerns, competition, and market share losses. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.

ZTS securities class action misleading statements Companion Animal products Librela Simparica Trio Apoquel Cytopoint

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about product performance, market share losses, weakening veterinarian adoption, and failure to disclose material safety concerns and competitive pressures affecting its flagship Companion Animal products.

Negative Jul 16, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false statements about product growth and market positioning. The complaint claims the company failed to disclose weakening adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales of dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are encouraged to join the case.

ZTS class action lawsuit securities fraud Librela Simparica Trio Apoquel Cytopoint market share loss

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements about product performance, market share losses, and failure to disclose safety concerns and competitive pressures affecting key revenue-generating products in the Companion Animal segment.

Negative Jul 14, 2026 • 14:54 UTC GlobeNewswire Inc. • Suewallst

ZTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zoetis Inc. Securities Lawsuit - Contact SueWallSt

Zoetis Inc. faces a securities class action lawsuit covering January 14, 2025 through May 6, 2026, with CEO Kristin Peck and CFO Wetteny Joseph named as individual defendants. The lawsuit alleges they certified misleading statements about companion animal product performance while safety concerns and competitive losses mounted. Zoetis shares fell 21.5% to $87.31 on May 7, 2026 following corrective disclosures. The lead plaintiff deadline is set for July 27, 2026.

ZTS securities class action misleading statements Sarbanes-Oxley certification Section 20(a) control person liability Librela safety concerns competitive market share losses lead plaintiff deadline

Sentiment note

Company faces securities class action lawsuit alleging material misstatements about product performance, with executives personally liable under Sarbanes-Oxley. Stock declined 21.5% following corrective disclosures, and products face safety concerns and competitive losses.

Neutral Jul 13, 2026 • 11:32 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Veterinary Lab Automation Global Market Report 2023 Now Available, Covers Asia-Pacific, North America, Europe, and More

The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.

IDXX TMO ABT SMMNY veterinary lab automation diagnostic solutions AI integration robotic workflows

Sentiment note

Listed as a prominent company in the market but no specific recent developments or strategic moves mentioned in the article.

Negative Jul 10, 2026 • 21:49 UTC GlobeNewswire Inc. • Rosen Law Firm

ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Rosen Law Firm is notifying Zoetis Inc. investors who purchased securities between January 14, 2025 and May 6, 2026 of an important July 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of flagship products Librela and Simparica Trio, as well as market share losses in dermatology products due to FDA safety warnings and increased competition.

ZTS securities class action lead plaintiff deadline false statements market share loss Librela Simparica Trio Apoquel

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements about product performance, market share, and sales growth. The lawsuit claims Zoetis failed to disclose significant weakening in key product adoption and market share losses due to safety concerns and competition, resulting in investor damages.

Negative Jul 10, 2026 • 16:51 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false and misleading statements regarding its business operations between January 14, 2025 and May 6, 2026. The complaint alleges the company failed to disclose weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply as lead plaintiff.

ZTS class action lawsuit securities fraud misleading statements Librela Simparica Trio Apoquel Cytopoint

Sentiment note

The company faces a class action lawsuit alleging material misstatements and non-disclosure of significant business deterioration, including weakening product adoption due to safety concerns, substantial market share losses to competitors, and misleading positive statements about business prospects.

Negative Jul 6, 2026 • 17:48 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP announced a securities fraud class action lawsuit against Zoetis Inc., alleging the company made materially false statements and failed to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and reduced growth outlooks. The deadline to file a lead plaintiff motion is July 27, 2026.

ZTS securities fraud class action lawsuit Companion Animal portfolio Librela Simparica Trio market share loss competitive pressure

Sentiment note

The company faces a securities fraud lawsuit alleging material misstatements and non-disclosure of adverse business conditions. Stock prices fell significantly (3.8%, 13.8%, and 21.5%) following earnings announcements revealing weakened demand, increased competition, market share losses in key products (Librela, Simparica Trio, Apoquel, Cytopoint), and reduced growth guidance. The allegations suggest management failed to adequately communicate deteriorating business conditions to investors.

Negative Jul 6, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false and misleading statements about its Companion Animal segment products. The complaint claims the company failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses for Simparica Trio to lower-priced competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are eligible to join the class action.

ZTS securities fraud class action lawsuit Librela Simparica Trio Apoquel Cytopoint market share loss

Sentiment note

The company faces a securities fraud class action lawsuit alleging material misstatements and non-disclosure regarding significant product performance issues, including weakening adoption of key products, market share losses to competitors, and undisclosed FDA safety concerns affecting investor confidence.

Negative Jul 4, 2026 • 22:15 UTC GlobeNewswire Inc. • Rosen Law Firm

ZTS DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Rosen Law Firm has filed securities class action lawsuits against Zoetis Inc. and ChampionX Corporation. The Zoetis lawsuit alleges the company made false statements about market share and product adoption while failing to disclose weakening sales of key products like Librela and Simparica Trio due to safety concerns and increased competition. The lead plaintiff deadline for the Zoetis case is July 27, 2026.

ZTS securities class action false statements market share decline product safety concerns investor losses lead plaintiff deadline

Sentiment note

The company is accused of making false and misleading statements about product performance and market adoption while concealing significant weakening in key product lines (Librela, Simparica Trio, Apoquel, Cytopoint) due to safety warnings, competition, and market share losses. These allegations resulted in investor damages.

Negative Jul 4, 2026 • 22:15 UTC GlobeNewswire Inc. • Rosen Law Firm

ZTS 截止日期提醒：全球頂級律師事務所 ROSEN 建議損失超過 10 萬美元的 Zoetis Inc. 投資者趕及對 ZTS 提出證券集體訴訟的重要截止日期前聘請律師

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025 and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements about market share growth and product adoption while failing to disclose significant market share losses in key products including Librela, Simparica Trio, Apoquel, and Cytopoint due to increased competition and FDA safety warnings. The deadline to apply as lead plaintiff is July 27, 2026.

ZTS securities class action false statements market share loss companion animal products FDA safety warning investor losses

Sentiment note

The company is accused of making false and misleading statements about product performance and market adoption while concealing significant market share losses in flagship products (Librela, Simparica Trio, Apoquel, Cytopoint) due to competition and regulatory concerns. These allegations suggest material misrepresentation to investors, resulting in financial losses.

Negative Jul 2, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud. The complaint claims the company made false statements about its Companion Animal segment products, including Librela, Simparica Trio, Apoquel, and Cytopoint, while failing to disclose weakening veterinarian adoption, market share losses to competitors, and FDA safety concerns. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 may be eligible to join the case.

ZTS class action lawsuit securities fraud Companion Animal segment Librela Simparica Trio Apoquel Cytopoint

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about product growth and market positioning. The complaint details significant weakening in key product adoption, market share losses to competitors, and undisclosed FDA safety concerns, all of which indicate serious operational and compliance issues that resulted in investor harm.

Negative Jul 2, 2026 • 14:32 UTC GlobeNewswire Inc. • Schall Law Firm

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has filed a class action lawsuit against Zoetis Inc. for alleged securities fraud, claiming the company made false and misleading statements regarding its products. The lawsuit alleges that Zoetis failed to disclose weakening prescription growth for Librela following FDA safety warnings about neurological complications in dogs, as well as market share losses for its Trio, Apoquel, and Cytopoint products. Investors who purchased securities between January 14, 2025 and May 6, 2026 are encouraged to join the case.

ZTS class action lawsuit securities fraud false statements Librela FDA safety warnings market share loss veterinary products

Sentiment note

The company is accused of making false and misleading statements to investors regarding product performance. Specific allegations include undisclosed weakening prescription growth for Librela due to FDA safety warnings about neurological complications, and significant market share losses across multiple product lines (Trio, Apoquel, and Cytopoint), resulting in investor losses.